A First For Wall Street, But Just The Beginning For MindMed
“This continues to show our expansion beyond just the programs we've already got in our development pipeline. It's more evidence of the value of our collaboration with Dr. Liechti and University Hospital Basel,” said CEO Rob Barrow in an exclusive interview. The exec. said that the new program highlights the company’s edge, as it is able to research a wide variety of psychedelic molecules without having to deploy significant efforts on new infrastructure or personnel.
For these reasons MindMed is still cautious not to announce any formal development program to achieve FDA or EMA approval on DMT. “I think a lot has stagnated on this idea that there's one treatment indication for psychedelics,” says Barrow, emphasizing that these molecules have a broad potential beyond “just depression and anxiety.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Forbes - 🏆 394. / 53 Read more »
Source: trtworld - 🏆 101. / 63 Read more »
Why are we promoting any medical treatments by celebrities? good Rookies
Source: USATODAY - 🏆 100. / 63 Read more »
Source: TODAYshow - 🏆 389. / 55 Read more »
Source: epicurious - 🏆 114. / 63 Read more »
See the pitch deck that clinical-trial firm Castor used to raise $45MThis entrepreneur thinks computer simulations could replace human drug-trial participants by 2035. See the pitch deck that helped his startup raise $45 million.
Source: BusinessInsider - 🏆 729. / 51 Read more »